Methylphenidate and Dyslipidemia

Gideon Charach, Nechemia Kaysar, Alexander Rabinovich, Ori Argov, Moshe WeintraubInTech 2012 · DOI · OpenAlex

Abstract

Methylphenidate is a piperidine derivative, structurally related to amphetamines and acts as a CNS stimulant. Methylphenidate has been widely used since 1937 for numerous indications including attention deficit hyperactivity disorder (ADHD), narcolepsy, cataplexy (3) and conduct disorder (4) in children and adolescents as well as adults (4). Although it has been indicated for ADHD since 1957 it has gained widespread use during the last two decades (5). Methylphenidate was found to affect brain sterol metabolism in mice by inhibition of the incorporation of its precursors, acetate and glucose, into the brain and by reduction of the brain’s sterol levels (6). This reduction was found to occur within 24 hours in the neuronal cellular membrane, the site of methylphenidate’s action (6).

Introduction

Long-term pharmacological treatment for ADHD often begins in childhood and continues through adulthood. Because these treatments are prolonged, understanding their metabolic consequences is vital for preventing future cardiovascular disease. Many classes of psychotropic drugs—such as second-generation antipsychotics (e.g., olanzapine) and mood stabilizers (e.g., lithium)—are well-documented triggers for weight gain and secondary dyslipidemia (abnormal levels of lipids in the blood). Dyslipidemia is a primary risk factor for atherosclerosis and heart disease.

This study investigates whether Methylphenidate, a central nervous system (CNS) stimulant, shares these negative metabolic side effects or if its unique mechanism of action leads to a different outcome. While many psychotropic medications are notorious for causing weight gain and metabolic issues, this research suggests that Methylphenidate may actually improve a patient's lipid profile.

Methods and Study Population

The researchers conducted a randomized clinical study involving 42 outpatients (22 males, 20 females) previously diagnosed with ADHD. The study tracked patients over a three-month period of Methylphenidate treatment. The median age of the cohort was 16 years, with a range from 11 to 31 years.

To evaluate metabolic impact, the team measured several key biomarkers at baseline and at the end of the three months:

  • Body Mass Index (BMI)
  • Lipid Profile: Total cholesterol (T-Chol), High-density lipoprotein (HDL-c), Low-density lipoprotein (LDL-c), and Triglycerides (Trigl).
  • Apolipoproteins: Apo A, Apo B, and Lipoprotein (a) [Lp(a)].
Baseline characteristics of the study population

The study utilized the Wilcoxon test for statistical analysis to determine the significance of the changes observed before and after treatment.

Key Results

The quantitative results showed a clear trend toward improved cardiovascular markers without the weight gain typically associated with other psychiatric treatments.

Changes in metabolic markers after three months of Methylphenidate treatment
  • Total Cholesterol: Dropped by a median of 9 mg/dl (p=0.0002).
  • LDL-c ("Bad" Cholesterol): Decreased by 5 mg/dl (p=0.016).
  • Triglycerides: Decreased by 8 mg/dl (p=0.016).
  • Lipoprotein (a): Showed a statistically significant decrease (p=0.0007).
  • BMI: Remained stable, with a median change of 0 (p=0.24).
  • Non-Significant Changes: Changes in HDL-c and Apolipoproteins A and B were not statistically significant.

Discussion

The study highlights Methylphenidate as a "metabolic exception" among psychiatric drugs. Unlike treatments that induce weight gain, Methylphenidate did not cause weight gain in the study group. The authors propose that this lipid-lowering effect is tied to the drug's impact on synaptic dopamine. By stimulating dopamine release, the drug may trigger an "anorexigenic effect" (appetite suppression) via hypothalamic pathways, specifically involving the cocaine-amphetamine-regulated transcript (CART).

Furthermore, while previous research showed Methylphenidate affects sterol metabolism specifically within the brain, this study bridges that gap by demonstrating a significant impact on plasma lipid levels. One of the most surprising findings was the significant reduction in Lipoprotein (a), an independent and often difficult-to-treat risk factor for atherosclerosis.

Limitations and Future Work

The authors note that these conclusions are tentative due to several factors:

  • Sample Size and Age: The study was small (n=42) and consisted mostly of teenagers. It is unclear if these results would be identical in an older adult population.
  • Study Duration: Three months is a short window. The researchers cannot yet predict if these lipid improvements persist over years or if they definitively prevent the development of atherosclerosis.
  • Dropout Rate: A high rate of early dropouts can introduce bias into the results.

Future directions include larger, long-term, well-designed trials to establish the definitive metabolic effects of Methylphenidate and to see if these biochemical changes translate into a lower incidence of heart disease in the long run.

Summary updated

Abstract

Methylphenidate is a piperidine derivative, structurally related to amphetamines and acts as a CNS stimulant. Methylphenidate has been widely used since 1937 for numerous indications including attention deficit hyperactivity disorder (ADHD), narcolepsy, cataplexy (3) and conduct disorder (4) in children and adolescents as well as adults (4). Although it has been indicated for ADHD since 1957 it has gained widespread use during the last two decades (5). Methylphenidate was found to affect brain sterol metabolism in mice by inhibition of the incorporation of its precursors, acetate and glucose, into the brain and by reduction of the brain’s sterol levels (6). This reduction was found to occur within 24 hours in the neuronal cellular membrane, the site of methylphenidate’s action (6).
BibTeX
@inproceedings{charach2012methylphenidate,
  author = {Gideon Charach and Nechemia Kaysar and Alexander Rabinovich and Ori Argov and Moshe Weintraub},
  title = {{Methylphenidate and Dyslipidemia}},
  booktitle = {InTech},
  year = {2012},
  doi = {10.5772/31140},
}
Figure